## Ewa Sierko

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/795036/publications.pdf

Version: 2024-02-01

471477 302107 1,637 67 17 39 citations h-index g-index papers 69 69 69 2362 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	Platelets and Angiogenesis in Malignancy. Seminars in Thrombosis and Hemostasis, 2004, 30, 95-108.	2.7	282
2	Platelets and cancer angiogenesis nexus. Cancer and Metastasis Reviews, 2017, 36, 249-262.	5.9	172
3	Protease-activated receptors (PARs)—biology and role in cancer invasion and metastasis. Cancer and Metastasis Reviews, 2015, 34, 775-796.	5.9	109
4	The Hemostatic System and Angiogenesis in Malignancy. Neoplasia, 2001, 3, 371-384.	5.3	108
5	Inhibition of Platelet Function: Does It Offer a Chance of Better Cancer Progression Control?. Seminars in Thrombosis and Hemostasis, 2007, 33, 712-721.	2.7	108
6	The Role of Tissue Factor Pathway Inhibitor-2 in Cancer Biology. Seminars in Thrombosis and Hemostasis, 2007, 33, 653-659.	2.7	86
7	Thrombin—unique coagulation system protein with multifaceted impacts on cancer and metastasis. Cancer and Metastasis Reviews, 2016, 35, 213-233.	5.9	68
8	Contribution of the Hemostatic System to Angiogenesis in Cancer. Seminars in Thrombosis and Hemostasis, 2004, 30, 5-20.	2.7	59
9	Tissue Factor-Dependent Coagulation Activation and Impaired Fibrinolysis in Situ in Gastric Cancer. Seminars in Thrombosis and Hemostasis, 2003, 29, 291-300.	2.7	49
10	Antiplatelet agents for cancer treatment: a real perspective or just an echo from the past?. Cancer and Metastasis Reviews, 2017, 36, 305-329.	5.9	46
11	Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue. Thrombosis and Haemostasis, 2003, 90, 140-146.	3 <b>.</b> 4	41
12	Expression of tissue factor pathway inhibitor (TFPI) in human breast and colon cancer tissue. Thrombosis and Haemostasis, 2010, 103, 198-204.	3 <b>.</b> 4	41
13	PET/MRI-guided GTV delineation during radiotherapy planning in patients with squamous cell carcinoma of the tongue. Strahlentherapie Und Onkologie, 2019, 195, 780-791.	2.0	33
14	Usefulness of Hybrid PET/MRI in Clinical Evaluation of Head and Neck Cancer Patients. Cancers, 2020, 12, 511.	3.7	32
15	The Role of Hemostatic System Inhibitors in Malignancy. Seminars in Thrombosis and Hemostasis, 2007, 33, 621-642.	2.7	27
16	Co-localization of Protein Z, Protein Z-Dependent protease inhibitor and coagulation factor X in human colon cancer tissue: Implications for coagulation regulation on tumor cells. Thrombosis Research, 2012, 129, e112-e118.	1.7	25
17	Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue. Thrombosis and Haemostasis, 2003, 90, 140-6.	3.4	21
18	Endothelial Protein C Receptor (EPCR), Protease Activated Receptor-1 (PAR-1) and Their Interplay in Cancer Growth and Metastatic Dissemination. Cancers, 2019, 11, 51.	3.7	20

#	Article	IF	Citations
19	Systematic biobanking, novel imaging techniques, and advanced molecular analysis for precise tumor diagnosis and therapy: The Polish MOBIT project. Advances in Medical Sciences, 2017, 62, 405-413.	2.1	18
20	Expression of protein C (PC), protein S (PS) and thrombomodulin (TM) in human colorectal cancer. Thrombosis Research, 2010, 125, e71-e75.	1.7	17
21	Pain management during radiotherapy and radiochemotherapy in oropharyngeal cancer patients: single-institution experience. International Dental Journal, 2015, 65, 242-248.	2.6	17
22	Personalized Radiation Therapy in Cancer Pain Management. Cancers, 2019, 11, 390.	3.7	17
23	Identification of protein changes in the blood plasma of lung cancer patients subjected to chemotherapy using a 2D-DIGE approach. PLoS ONE, 2019, 14, e0223840.	2.5	16
24	Protein Z-dependent protease inhibitor (ZPI) is present in loco in human breast cancer tissue. Thrombosis and Haemostasis, 2010, 104, 183-185.	3.4	15
25	Protein Z is present in human breast cancer tissue. International Journal of Hematology, 2011, 93, 681-683.	1.6	15
26	Protein Z/protein Z-dependent protease inhibitor system in human non-small-cell lung cancer tissue. Thrombosis Research, 2012, 129, e92-e96.	1.7	14
27	The Ability of Metabolomics to Discriminate Non-Small-Cell Lung Cancer Subtypes Depends on the Stage of the Disease and the Type of Material Studied. Cancers, 2021, 13, 3314.	3.7	14
28	Is There an Interplay between Oral Microbiome, Head and Neck Carcinoma and Radiation-Induced Oral Mucositis?. Cancers, 2021, 13, 5902.	3.7	14
29	Protein Z/protein Z-dependent protease inhibitor system in loco in human gastric cancer. Annals of Hematology, 2014, 93, 779-784.	1.8	13
30	Elevated Microparticles, Thrombin-antithrombin and VEGF Levels in Colorectal Cancer Patients Undergoing Chemotherapy. Pathology and Oncology Research, 2020, 26, 2499-2507.	1.9	13
31	Localization of Protein Z (PZ) In Situ in Human Neoplastic Tissues Blood, 2004, 104, 3958-3958.	1.4	13
32	Granulocyte-Colony Stimulating Factor Receptor, Tissue Factor, and VEGF-R Bound VEGF in Human Breast Cancer In Loco. Advances in Clinical and Experimental Medicine, 2016, 25, 505-511.	1.4	10
33	Occurrence of Components of Fibrinolytic Pathways in Situ in Laryngeal Cancer. Seminars in Thrombosis and Hemostasis, 2003, 29, 317-320.	2.7	7
34	Awareness of head and neck cancer – a multicentre survey among young respondents in Poland. International Dental Journal, 2018, 68, 441-449.	2.6	7
35	Thromboprophylaxis in the End-of-Life Cancer Care: The Update. Cancers, 2020, 12, 600.	3.7	7
36	Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question?. Wspolczesna Onkologia, 2016, 2, 102-108.	1.4	6

#	Article	IF	CITATIONS
37	Co-localization of Coagulation Factor X and its Inhibitory System, PZ/ZPI, in Human Endometrial Cancer Tissue. In Vivo, 2019, 33, 771-776.	1.3	6
38	TFPI (Tissue Factor Pathway Inhibitor) Is Present in Breast Cancer Tumor Cells Blood, 2006, 108, 4035-4035.	1.4	6
39	Interfering with Hemostatic System Components: Possible New Approaches to Antiangiogenic Therapy. Seminars in Thrombosis and Hemostasis, 2004, 30, 145-156.	2.7	5
40	Simultaneous occurrence of non-Hodgkin lymphoma, renal cell carcinoma and oncocytoma: A case report. Molecular and Clinical Oncology, 2016, 5, 455-457.	1.0	5
41	Protease-activated receptors – biology and role in cancer. Postepy Higieny I Medycyny Doswiadczalnej, 2016, 70, 775-786.	0.1	5
42	Co-localization of prothrombin fragment F1+2 and VEGF-R2-bound VEGF in human colon cancer. Anticancer Research, 2011, 31, 843-7.	1.1	5
43	Thromboprophylaxis in cancer patients in hospice. Advances in Clinical and Experimental Medicine, 2018, 27, 283-289.	1.4	4
44	Massive saddle pulmonary embolism during radiochemotherapy of head and neck cancer. Polish Archives of Internal Medicine, 2017, 127, 561-563.	0.4	4
45	Application of two-dimensional difference gel electrophoresis to identify protein changes between center, margin, and adjacent non-tumor tissues obtained from non-small-cell lung cancer with adenocarcinoma or squamous cell carcinoma subtype. PLoS ONE, 2022, 17, e0268073.	2.5	4
46	Endothelial Microparticles and Blood Coagulation Activation in Head and Neck Cancer Patients Undergoing Radiotherapy or Radiochemotherapy. In Vivo, 2019, 33, 627-632.	1.3	3
47	PO-28 Expression of tissue factor (TF), tissue factor pathway inhibitor (TFPI), factor IX and factor X in breast cancer: comparison between primary tumor and metastatic lesions in regional lymph nodes. Thrombosis Research, 2007, 120, S154.	1.7	2
48	The Polish Cancer Anemia Survey (POLCAS): a retrospective multicenter study of 999 cases. International Journal of Hematology, 2009, 89, 276-284.	1.6	2
49	Psychological, Physical, and Social Situation of Polish Patients With Colorectal Cancer Undergoing First-Line Palliative Chemotherapy. Oncology Nursing Forum, 2011, 38, E253-E259.	1.2	2
50	Positron Emission Tomography Scanning in the Management of Hodgkin Lymphoma Patients: A Single-Institution Experience. Advances in Clinical and Experimental Medicine, 2016, 25, 1185-1192.	1.4	2
51	Guidelines for the prevention and treatment of venous thromboembolism in non-surgically treated cancer patients. Nowotwory, 2016, 66, 326-350.	0.3	2
52	The Learning Curve and Inter-Observer Variability in Contouring the Hippocampus under the Hippocampal Sparing Guidelines of Radiation Therapy Oncology Group 0933. Current Oncology, 2022, 29, 2564-2574.	2.2	2
53	Inhibitors of Hemostatic System in Cancer: Basic and Clinical Aspects. Seminars in Thrombosis and Hemostasis, 2007, 33, 619-620.	2.7	1
54	Expression of Protein Z-Dependent Protease Inhibitor (ZPI) In Situ in Different Malignant Tumors Blood, 2004, 104, 3959-3959.	1.4	1

#	Article	IF	CITATIONS
55	Heterogeneous Expression of Protein C (PC), Protein S (PS) and Thrombomodulin (TM) in Human Colon Cancer Tissue Blood, 2006, 108, 4037-4037.	1.4	1
56	Hippocampal sparing in brain radiotherapy. Nowotwory, 2016, 66, 299-306.	0.3	1
57	Actual, Personalized Approaches to Preserve Cognitive Functions in Brain Metastases Breast Cancer Patients. Cancers, 2022, 14, 3119.	3.7	1
58	882 poster 3-YEAR OVERALL SURVIVAL FOR INOPERABLE NON-SMALL CELL LUNG CARCINOMA PATIENTS TREATED WITH RA-DIOCHEMOTHERAPY $\hat{a} \in$ SINGLE-INSTITUTION RETROSPECTIVE ANALYSIS Radiotherapy and Oncology, 2011, 99, S340.	0.6	0
59	924 poster ADIUVANT RADIOCHEMOTHERAPY FOR GASTRIC CANCER PATIENTS – SINGLE-INSTITUTION RETROSPECTIVE EXPERIENCE Radiotherapy and Oncology, 2011, 99, S355.	0.6	0
60	Testicular Doses in Image Guided Step-and-Shoot Intensity Modulated Radiation Therapy of Prostate Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2013, 87, S377.	0.8	0
61	Testicular Dose Contributed by Image-Guided Intensity Modulated Radiation Therapy (IMRT) in Prostate Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2014, 90, S426.	0.8	0
62	EP-1179: Usefulness of [18F]FDG-PET/MRI in clinical evaluation of head and neck cancer (HNC) patients (pts). Radiotherapy and Oncology, 2018, 127, S660-S661.	0.6	0
63	Endothelial Microparticles and Vascular Endothelial Growth Factor in Patients With Head and Neck Cancer Undergoing Radiotherapy or Radiochemotherapy. In Vivo, 2019, 33, 581-586.	1.3	0
64	Pre-Processing Method for Contouring the Uptake Levels of [18F] FDG for Enhanced Specificity of PET Imaging of Solitary Hypermetabolic Pulmonary Nodules. Journal of Clinical Medicine, 2021, 10, 1430.	2.4	0
65	Comparative Analysis of Coagulation System Proteins Distribution in Breast Cancer Primary Lesions and Lymph Node Metastases Blood, 2007, 110, 3137-3137.	1.4	0
66	Wszczepialne systemy dostępu naczyniowego u chorych na nowotwory. Nowotwory, 2015, 65, 302-316.	0.3	0
67	Is AIO belly board device advantageous in all rectal cancer patients. Nowotwory, 2018, 67, 342-348.	0.3	0